
Draft

Advisory Board on Radiation and Worker Health
National Institute for Occupational Safety and Health

Task 3: A Protocol to Review Program Evaluation Reports by the National Institute for Occupational Safety and Health

Contract No. 75D30124F19451
Document No. SCA-PR2025-001, Revision 1

Prepared by

Kathleen Behling

SC&A, Inc.
2200 Wilson Blvd., Suite 300
Arlington, VA 22201-3324

July 6, 2026

DISCLAIMER

This is a working document provided by the Centers for Disease Control and Prevention (CDC) technical support contractor, SC&A for use in discussions with the National Institute for Occupational Safety and Health (NIOSH) and the Advisory Board on Radiation and Worker Health (ABRWH), including its Working Groups or Subcommittees. Documents produced by SC&A, such as memorandum, white paper, draft or working documents are not final NIOSH or ABRWH products or positions, unless specifically marked as such. This document prepared by SC&A represents its preliminary evaluation on technical issues.

NOTICE: *This document has been reviewed to identify and redact any information that is protected by the Privacy Act 5 U.S.C. § 552a and has been cleared for distribution.*

Effective date: 7/6/2026	Revision No. 1 (Draft)	Document No.: SCA-PR2025-001	Page 2 of 9
--------------------------	------------------------	------------------------------	-------------

SC&A, Inc. technical support for the Advisory Board on Radiation and Worker Health's review of NIOSH dose reconstruction program

Document title	Task 3: A Protocol to Review Program Evaluation Reports by the National Institute for Occupational Safety and Health
Document number	SCA-PR2025-001
Revision number	1 (Draft)
Supersedes	0 (Draft)
Effective date	July 6, 2026
Task manager	Kathleen Behling [signature on file]
Project manager	Bob Barton, Certified Health Physicist (CHP) [signature on file]
Document reviewer	Bob Barton, CHP [signature on file]

Record of revisions

Revision number	Effective date	Description of revision
0 (Draft)	3/26/2025	Initial issue
1 (Draft)	7/6/2026	Removed the term "consensus" from Subtask 2. Minor wording changes were introduced to enhance the clarity of subtask 3. Added a paragraph to section 3 that gives the date the Subcommittee for Procedure Reviews approved the revised protocol. Occasional rewording to meet current CDC plain language requirements. Updated acronyms and references.

Table of Contents

Abbreviations and Acronyms..... 4

1 Background Information..... 5

2 The Evolution of SC&A’s Review Process for Program Evaluation Reports..... 5

3 SC&A’s 2025 Proposed Revision of Program Evaluation Report Review Protocol .. 7

4 Summary Conclusions..... 8

5 References 9

Abbreviations and Acronyms

ABRWH, Board	Advisory Board on Radiation and Worker Health
CDC	Centers for Disease Control and Prevention
CHP	Certified Health Physicist
DFO	Designated Federal Official
DR	dose reconstruction
NIOSH	National Institute for Occupational Safety and Health
OCAS	Office of Compensation Analysis and Support
ORAUT	Oak Ridge Associated Universities Team
PER	program evaluation report
SPR	Subcommittee for Procedure Reviews

1 Background Information

To support dose reconstruction (DR), the National Institute for Occupational Safety and Health (NIOSH) and Oak Ridge Associated Universities Team (ORAUT) have assembled a large body of guidance documents, workbooks, computer codes, and tools. In recognition that all these supporting elements may be subject to revisions, provisions exist for evaluating the effect of such programmatic revisions on the outcome of previously completed DRs. Such revisions may be prompted by document revisions due to new information, updated clarification of current DR guidance, general changes in policy, and/or regular programmatic improvements.

The process for evaluating the potential impact of programmatic changes on previously completed DRs was previously proceduralized in the Office of Compensation Analysis and Support (OCAS) procedure OCAS-PR-008, revision 2, dated December 6, 2006 (NIOSH, 2006). This procedure described the format and methodology to be employed in preparing a program evaluation report (PER) and, when necessary, a program evaluation plan, which served as a formal notification of an impending PER.

A PER critically evaluates the effects that a given issue or programmatic change may have on previously completed DRs. This includes a qualitative and quantitative assessment of potential impacts. Most important in this assessment is the potential impacts on the probability of causation of previously completed noncompensable DRs.

2 The Evolution of SC&A's Review Process for Program Evaluation Reports

The Advisory Board on Radiation and Worker Health (ABRWH, Board) and the Board's Subcommittee for Procedure Reviews (SPR) began tasking SC&A with the review of PERs in 2007. SC&A's initial PER reviews and review protocol have evolved over time as follows:

- **June 12, 2007:** At the 47th Board Meeting, the Designated Federal Official (DFO) first requested that SC&A submit a cost proposal for the review of 30 procedures and three PERs (ABRWH, 2007a, pp. 241–242).
- **June 23, 2007:** SC&A submitted a cost proposal to the CDC Contracting Office that included a proposal for reviewing PERs. SC&A proposed a review protocol that consisted of six subtasks as follows:
 - Subtask 1: Conduct a critical review and analysis of the “issue” that served as the basis for the PER.
 - Subtask 2: Assess NIOSH's evaluation/characterization of the “issue” and its potential impacts on dose reconstruction.
 - Subtask 3: Assess NIOSH's specific methods for corrective action.
 - Subtask 4: Evaluate the PER's stated approach for identifying the universe of potentially affected DRs; and assess the criteria by which a subset of potentially affected DRs was selected for reevaluation.

- Subtask 5: Conduct audits of DRs affected by a PER under review.
- Subtask 6: SC&A will prepare a comprehensive written report that contains the results of our findings associated with of the all above-stated subtasks along with our review conclusions.
- **June 26, 2007:** An SPR teleconference briefly addressed SC&A’s proposed review of PERs consisting of six subtasks (ABRWH SPR, 2007, pp. 63–68). During the SPR meeting, it was noted that SC&A had completed its review of four PERs. However, SC&A’s review of these four PERs was performed by means of the generic protocol used for the review of NIOSH’s implementation guides, procedures, and technical basis documents.
- **July 19, 2007:** The Board continued its discussion about SC&A’s proposed review protocol for PERs and approved SC&A’s PER protocol to include six subtasks (ABRWH, 2007b, pp. 41–46).
- **November 27, 2007:** At a teleconference meeting, the Board authorized SC&A to begin review of OCAS-PER-009 (NIOSH, 2007; “PER-009”), along with the audit of three DRs (ABRWH, 2007c, pp. 96–101).
- **June 20, 2008:** SC&A issued a [final draft report](#) pertaining to our review of PER-009 (SC&A, 2008). During discussions of SC&A’s review of PER-009, the DFO, in behalf of the Contract Evaluation Panel, recommended eliminating subtask 1 of the SC&A proposed protocol for the review of PERs.
- **December 1, 2009:** SC&A issued revision 1 (SC&A, 2009) of the protocol to review NIOSH PERs, which consisted of five subtasks as follows:
 - Subtask 1: Assess NIOSH’s evaluation/characterization of the “issue” and its potential impacts on dose reconstruction. Our assessment intends to ensure that the “issue” was fully understood and characterized in the PER.
 - Subtask 2: Assess NIOSH’s specific methods for corrective action. In instances where the PER involves a technical issue, SC&A will review the scientific basis and/or sources of information to ensure the credibility of the corrective action and its consistency with current/consensus science.
 - Subtask 3: Evaluate the PER’s stated approach for identifying the universe of potentially affected DRs; and assess the criteria by which a subset of potentially affected DRs was selected for reevaluation. The second step may have important implications in instances where the universe of DRs is too large and, for reasons of practicality, NIOSH’s reevaluation is confined to a subset of DRs. In behalf of subtask 4, SC&A will also evaluate and give due consideration to the timeliness for the completion of the PER.

- Subtask 4: Conduct audits of DRs affected by a PER under review. The number of DRs selected for audit for a given PER will vary. (It is assumed that the selection of the DRs and the total number of DR audits per PER will be made by the Advisory Board.) It is further anticipated that the scope of the DR audits may vary and reflect whether the original DR was based on a maximized dose reconstruction or whether the original DR reflects a best estimate. The difference in audit strategy is based on the following:
 - Audits of DRs originally derived by best estimates will be based on a highly focused review inasmuch as all elements of the dose reconstruction other than the element(s) defined in the PER can be assumed to remain unchanged.
 - A DR that was originally based on a maximized (or partially maximized) approach may not only be revised for dose element(s) affected by the PER but may be subject to revision(s) for dose elements that were previously based on maximized assumptions. Audits of such cases will require a comprehensive review.
- Subtask 5: Prepare a comprehensive written report that contains the results of above-stated subtasks along with our review conclusions.

3 SC&A's 2025 Proposed Revision of Program Evaluation Report Review Protocol

As a result of SC&A's 2024 contract rebid, SC&A revisited the PER protocols to determine if the review guidance was still applicable. As a result, SC&A determined that not all the subtasks conformed to our current practices. Therefore, at the November 8, 2024, SPR meeting, SC&A requested and obtained approval from the SPR to propose modifications to the PER review protocol (ABRWH SPR, 2024, pp. 19–20).

In March 2025, SC&A proposed a revised PER protocol in which the number of subtasks be reduced from five to four and the descriptions of subtasks 2, 3, and 4 be expanded to include more details (SC&A, 2025).

SC&A presented its updated PER protocol to the SPR at the June 5, 2026, meeting. During the meeting, the SPR approved the revised protocol. However, based on discussions with NIOSH, the SPR and SC&A agreed that the term "consensus" would be removed from subtask 2, along with minor wording changes to clarify subtask 3. This report presents the final revised protocol:

- **Subtask 1:** Assess NIOSH's evaluation and characterization of the issue addressed in the PER and its potential impacts on DR. Our assessment intends to ensure that the issue was fully understood and characterized in the PER. [Note: this subtask remains unchanged from the previous review protocol.]
- **Subtask 2:** Assess NIOSH's specific methods for corrective action. When the PER involves a technical issue that is supported by documents (e.g., white papers, technical

Effective date: 7/6/2026	Revision No. 1 (Draft)	Document No.: SCA-PR2025-001	Page 8 of 9
--------------------------	------------------------	------------------------------	-------------

information bulletins, procedures) that have not yet been subjected to a formal SC&A review, subtask 2 will include a review of the scientific basis and/or sources of information to ensure the credibility of the corrective action and its consistency with current science. Conversely, if such technical documentation has been formalized and previously subjected to a review by SC&A, subtask 2 will simply provide a summary and conclusion of that review process.

- **Subtask 3:** Evaluate the PER's stated approach for identifying the universe of potentially affected DRs and assess the criteria by which a subset of potentially affected DRs was selected for reevaluation. The second step may have important implications where the universe of previously denied DRs is very large and, for reasons of practicality, NIOSH's reevaluation was confined to a subset of DRs that, based on their scientific judgment, had the potential to be significantly affected by the PER. As part of subtask 3, SC&A will also provide the SPR with an evaluation of the timeliness of PER's completion.

SC&A will prepare a written report discussing the findings of our review of subtasks 1–3 for the SPR. This report will also provide recommendations for the case selection criteria for DRs that the Board may want to consider for SC&A's review under subtask 4. The sample size of DRs considered adequate for auditing a given PER will vary based on the changes that prompted the issuance of the PER, such as the number of exposure pathways impacted, number of target organs or tissues involved, monitoring methods, affected time period, etc.

- **Subtask 4:** Conduct audits of selected DRs affected by the PER under review. SC&A's review of these cases will typically be limited to reviewing only those methods and corrective actions introduced in the reevaluated dose that relate to issues addressed in the PER. However, if SC&A identifies questionable information or inconsistencies that warrant bringing an issue to the attention of the SPR, the review will be expanded as deemed appropriate. SC&A will provide the SPR with a comprehensive report of its DR review findings.

4 Summary Conclusions

SC&A began reviewing NIOSH PERs in 2007. Initially, SC&A's review protocol consisted of six subtasks. Due to a recommendation by the Contract Evaluation Panel to eliminate subtask 1, SC&A issued revision 1 of our PER protocol in 2009 with five subtasks.

In 2025, SC&A proposed a revised protocol consisting of four subtasks, described in section 3 of this document, that have been modified to reflect the current practices that have been accepted by the SPR and the Board. The primary reason for the decrease from five subtasks to four is the elimination of subtask 5, which called for a summary document of all previous subtasks. However, it is SC&A's opinion that this last subtask is not necessary because subtasks 1–3 are summarized in a single report already, which also serves to inform the Board on suggested criteria for case audits under subtask 4 (which is likewise documented in a report and presented to the Board).

Effective date: 7/6/2026	Revision No. 1 (Draft)	Document No.: SCA-PR2025-001	Page 9 of 9
--------------------------	------------------------	------------------------------	-------------

The SPR reviewed and approved SC&A’s proposed 2025 revision in June 2026. Further discussions among the SPR, NIOSH, and SC&A resulted in revisions to subtasks 2 and 3 as presented in this document.

5 References

Advisory Board on Radiation and Worker Health. (2007a). *Meeting 47* [Transcript of June 12, 2007, meeting]. <https://www.cdc.gov/niosh/ocas/pdfs/abrwh/tr061207.pdf>

Advisory Board on Radiation and Worker Health. (2007b). *Meeting 48* [Transcript of July 19, 2007, meeting]. <https://www.cdc.gov/niosh/ocas/pdfs/abrwh/tr071907.pdf>

Advisory Board on Radiation and Worker Health. (2007c). *Meeting 51* [Transcript of November 27, 2007, teleconference meeting]. <https://www.cdc.gov/niosh/ocas/pdfs/abrwh/tr112707.pdf>

Advisory Board on Radiation and Worker Health, Subcommittee for Procedure Reviews. (2007). *Working group Procedures Review* [Transcript of June 26, 2007, teleconference meeting]. <https://www.cdc.gov/niosh/ocas/pdfs/abrwh/tr062607.pdf>

Advisory Board on Radiation and Worker Health, Subcommittee for Procedure Reviews. (2024). *Friday, November 8, 2024* [Transcript of November 8, 2024, teleconference meeting]. <https://www.cdc.gov/niosh/ocas/pdfs/abrwh/2024/sctr110824-508.pdf>

National Institute for Occupational Safety and Health. (2006). *Preparation of program evaluation reports and program evaluation plans* (OCAS-PR-008, rev. 2).

National Institute for Occupational Safety and health. (2007). *Target organs for lymphoma* (OCAS-PER-009, rev. 0). <https://www.cdc.gov/niosh/ocas/pdfs/pers/oc-per9-r0.pdf>

SC&A, Inc. (2008). *A preliminary review of NIOSH’s program evaluation report OCAS-PER-009, “Target organs for lymphomas”* (SCA-TR-TASK3-0008, rev. 3). <https://www.cdc.gov/niosh/ocas/pdfs/abrwh/scarpts/sca-ocper9-r3.pdf>

SC&A, Inc. (2009). *A protocol to review NIOSH’s program evaluation reports (PERs)* (SCA-TR-PR2009-0002, rev. 1).

SC&A, Inc. (2025). *Task 3: A protocol to review NIOSH’s program evaluation reports* (SCA-PR2025-001, rev. 0). <https://www.cdc.gov/niosh/ocas/pdfs/abrwh/scarpts/sca-perprotocol-508.pdf>